Dr Ulysses M Magnanao, DO | |
1710 N Randall Rd, Suite 200, Elgin, IL 60123-9400 | |
(847) 214-5780 | |
(847) 214-5777 |
Full Name | Dr Ulysses M Magnanao |
---|---|
Gender | Male |
Speciality | Family Practice |
Experience | 29 Years |
Location | 1710 N Randall Rd, Elgin, Illinois |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1225020142 | NPI | - | NPPES |
1619414 | Other | IL | BCBS GROUP |
612034800 | Other | IL | IL DEPT OF LABOR |
036105671 | Medicaid | IL | |
05632414 | Other | IL | BCBS PROV # |
P01117452 | Other | IL | RAILROAD MEDICARE PTAN |
05632168 | Other | IL | BLUE CROSS & BLUE SHIELD |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 036105671 (Illinois) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Advocate Home Health Care Serv | Lombard, IL | Home health agency |
Advocate Sherman Hospital | Elgin, IL | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Advocate Health And Hospitals Corporation | 7810800935 | 2422 |
News Archive
Alder Biopharmaceuticals Inc. today announced it has received a $3.5 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2 clinical trial of ALD518/BMS-945429, an investigational antibody therapeutic that blocks interleukin-6 (IL-6), in Crohn's disease.
Chronic kidney disease (CKD) is caused by diabetes and hypertension. In 2017, the global prevalence of CKD was 9.1 percent, which is approximately 700 million cases.
A new and kinder chemistry promises cleaner and subsequently safer pharmaceuticals with fewer side-effects. The ground-breaking method, developed by a chemistry research group at the University of Copenhagen, is now published in the internationally renowned journal, Chemical Communications, as "Site-selective three component reaction for dual functionalization of peptides".
Biogen Idec today announced it has completed its purchase of Elan Corporation's interest in TYSABRI (natalizumab) and has gained full strategic, commercial and decision-making rights to TYSABRI.
› Verified 7 days ago
Entity Name | Advocate Health And Hospitals Corporation |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1700824455 PECOS PAC ID: 7810800935 Enrollment ID: O20031106000064 |
News Archive
Alder Biopharmaceuticals Inc. today announced it has received a $3.5 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2 clinical trial of ALD518/BMS-945429, an investigational antibody therapeutic that blocks interleukin-6 (IL-6), in Crohn's disease.
Chronic kidney disease (CKD) is caused by diabetes and hypertension. In 2017, the global prevalence of CKD was 9.1 percent, which is approximately 700 million cases.
A new and kinder chemistry promises cleaner and subsequently safer pharmaceuticals with fewer side-effects. The ground-breaking method, developed by a chemistry research group at the University of Copenhagen, is now published in the internationally renowned journal, Chemical Communications, as "Site-selective three component reaction for dual functionalization of peptides".
Biogen Idec today announced it has completed its purchase of Elan Corporation's interest in TYSABRI (natalizumab) and has gained full strategic, commercial and decision-making rights to TYSABRI.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Ulysses M Magnanao, DO 1710 N Randall Rd, Suite 200, Elgin, IL 60123-9400 Ph: (847) 214-5740 | Dr Ulysses M Magnanao, DO 1710 N Randall Rd, Suite 200, Elgin, IL 60123-9400 Ph: (847) 214-5780 |
News Archive
Alder Biopharmaceuticals Inc. today announced it has received a $3.5 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2 clinical trial of ALD518/BMS-945429, an investigational antibody therapeutic that blocks interleukin-6 (IL-6), in Crohn's disease.
Chronic kidney disease (CKD) is caused by diabetes and hypertension. In 2017, the global prevalence of CKD was 9.1 percent, which is approximately 700 million cases.
A new and kinder chemistry promises cleaner and subsequently safer pharmaceuticals with fewer side-effects. The ground-breaking method, developed by a chemistry research group at the University of Copenhagen, is now published in the internationally renowned journal, Chemical Communications, as "Site-selective three component reaction for dual functionalization of peptides".
Biogen Idec today announced it has completed its purchase of Elan Corporation's interest in TYSABRI (natalizumab) and has gained full strategic, commercial and decision-making rights to TYSABRI.
› Verified 7 days ago
Ailee Wang, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 87 N Airlite St, Elgin, IL 60123 Phone: 847-695-6611 | |
Dorothea Poulos, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 87 N Airlite St Ste 130, Elgin, IL 60123 Phone: 847-888-3661 Fax: 847-888-9964 | |
Dr. Ronald J Winters, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2350 Royal Blvd Ste 300, Elgin, IL 60123 Phone: 847-742-3120 Fax: 847-742-4021 | |
Anthony Francis Rizzo, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1550 N Randall Rd, Elgin, IL 60123 Phone: 815-398-9491 | |
Manapurathu Mathew, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 40 N Airlite St, Suite 4, Elgin, IL 60123 Phone: 847-695-8454 Fax: 847-695-9868 | |
Dr. Monica J. Fudala, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 820 Summit St # B4, Elgin, IL 60120 Phone: 847-306-7093 | |
Cheerag Patel, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 370 Summit St., Elgin, IL 60120 Phone: 847-608-4767 |